The Autoimmunity, Transplantation & Inflammatory Disease group is developing transformative therapies, including small molecules and biotherapeutics, that target the root cause of disease by modulating the immune system to restore health.
Our Cardiovascular & Metabolic Diseases team works to better understand the root causes of cardiovascular and metabolic diseases, and discover and develop therapies against relevant targets.
DAx catalyzes and drives transformative therapies for emerging, high-potential indications. Current research focuses on liver, respiratory and kidney diseases, as well as non-malignant blood disorders.
Our Immuno-Oncology researchers are developing a deep and diverse portfolio of potential immune treatments for cancer.
The mission of our Musculoskeletal Diseases research team is to restore mobility and independence to patients living with some of the most intractable of these conditions.
Our neuroscience research team works to discover transformative therapies that address the underlying cause of neurodegenerative, neurodevelopmental and psychiatric diseases to dramatically improve the lives of patients.
Our Oncology team is developing a robust portfolio of treatments that destroy tumors selectively and strip away their defenses.
The Ophthalmology research team is working to develop a diverse portfolio of compounds – small molecules, biologics and gene-based treatments – that protect and restore vision.
The Novartis Institute for Tropical Diseases is a drug discovery research institute dedicated to finding novel treatments for neglected tropical diseases, including malaria, cryptosporidiosis, and three major kinetoplastid diseases – human African trypanosomiasis, Chagas disease, and leishmaniasis.